The AstraZeneca share price just fell 8.4% in a day. Is it time to consider buying?

The AstraZeneca share price has fallen almost 25% since late August. Is there value on offer for investors after this huge fall?

| More on:

The content of this article was relevant at the time of publishing. Circumstances change continuously and caution should therefore be exercised when relying upon any content contained within this article.

Portrait of elderly man wearing white denim shirt and glasses looking up with hand on chin. Thoughtful senior entrepreneur, studio shot against grey background.

Image source: Getty Images

When investing, your capital is at risk. The value of your investments can go down as well as up and you may get back less than you put in.

Read More

The content of this article is provided for information purposes only and is not intended to be, nor does it constitute, any form of personal advice. Investments in a currency other than sterling are exposed to currency exchange risk. Currency exchange rates are constantly changing, which may affect the value of the investment in sterling terms. You could lose money in sterling even if the stock price rises in the currency of origin. Stocks listed on overseas exchanges may be subject to additional dealing and exchange rate charges, and may have other tax implications, and may not provide the same, or any, regulatory protection as in the UK.

You’re reading a free article with opinions that may differ from The Motley Fool’s Premium Investing Services. Become a Motley Fool member today to get instant access to our top analyst recommendations, in-depth research, investing resources, and more. Learn More.

The AstraZeneca (LSE: AZN) share price is in freefall at the moment. Yesterday (5 November), it fell 8.4%. Since late August, it has plummeted nearly 25%.

So, what’s going on here? And has the share price created a good buying opportunity for long-term investors to consider?

Created with Highcharts 11.4.3AstraZeneca Plc PriceZoom1M3M6MYTD1Y5Y10YALLwww.fool.co.uk

Share price crash

Let’s start with yesterday’s fall.

Should you invest £1,000 in NatWest Group right now?

When investing expert Mark Rogers has a stock tip, it can pay to listen. After all, the flagship Motley Fool Share Advisor newsletter he has run for nearly a decade has provided thousands of paying members with top stock recommendations from the UK and US markets. And right now, Mark thinks there are 6 standout stocks that investors should consider buying. Want to see if NatWest Group made the list?

See the 6 stocks

It seems this was primarily caused by a report that a number of senior executives at the pharma company’s China unit could be implicated in a major insurance fraud case.

Last week, AstraZeneca said that its China president Leon Wang was being investigated by authorities and would be standing down from his position.

However, according to financial media company Yicai, the investigation by Chinese authorities has now blown out to include ‘dozens’ of senior AstraZeneca executives, with multiple authorities getting involved.

It’s worth noting that problems in China have been plaguing the company for months now. In early September, police in the country detained five current and former employees of AstraZeneca for questioning about potential illegal activities. This issue was related to its collection of patient data and whether it infringed China’s data-privacy laws.

Sell rating

Another factor that has hurt the FTSE 100 stock in recent months is disappointing drug trial results. In mid-September, the shares fell after results from the company’s lung cancer trials showed that its experimental precision drug didn’t significantly improve overall survival results for patients.

Finally, there has been some negative broker commentary recently. For example, in September, analysts at Deutsche Bank slapped a Sell rating on the stock. It’s worth noting that yesterday, the same analysts described early data on AstraZeneca’s experimental weight loss pill as “somewhat underwhelming”.

So overall, there has been a lot of negative news for investors to digest here.

A buying opportunity?

But is now a good time to take a closer look at the stock?

My gut feeling is that it is.

The China issues are certainly a risk factor here. They could lead to reputational damage and/or large fines and put more pressure on the share price in the near term.

But I think the company can recover from these setbacks. I don’t think that they’re likely to impact the group too much in the long run.

As for the disappointing drug trial results, I don’t see these as the end of the world for the firm. That’s because AstraZeneca currently has nearly 200 drugs in its pipeline.

Turning to the valuation, the shares currently trade on a forward-looking price-to-earnings (P/E) ratio of about 14 after yesterday’s fall. That’s a relatively attractive valuation, in my view.

It’s worth pointing out that trying to ‘catch a falling knife’ can be dangerous. That’s because a stock in freefall can keep falling.

So, if I was interested in buying the stock, I would probably wait until it had stabilised a little. I’d also look to build a position over time and average out my entry prices.

Should you buy NatWest Group now?

Don’t make any big decisions yet.

Because Mark Rogers — The Motley Fool UK’s Director of Investing — has revealed 5 Shares for the Future of Energy.

And he believes they could bring spectacular returns over the next decade.

Since the war in Ukraine, nations everywhere are scrambling for energy independence, he says. Meanwhile, they’re hellbent on achieving net zero emissions. No guarantees, but history shows...

When such enormous changes hit a big industry, informed investors can potentially get rich.

So, with his new report, Mark’s aiming to put more investors in this enviable position.

Click the button below to find out how you can get your hands on the full report now, and as a thank you for your interest, we’ll send you one of the five picks — absolutely free!

Grab your FREE Energy recommendation now

Should you invest, the value of your investment may rise or fall and your capital is at risk. Before investing, your individual circumstances should be assessed. Consider taking independent financial advice.

Edward Sheldon has no position in any of the shares mentioned. The Motley Fool UK has recommended AstraZeneca Plc. Views expressed on the companies mentioned in this article are those of the writer and therefore may differ from the official recommendations we make in our subscription services such as Share Advisor, Hidden Winners and Pro. Here at The Motley Fool we believe that considering a diverse range of insights makes us better investors.

Our best passive income stock ideas

Do you like the idea of dividend income?

The prospect of investing in a company just once, then sitting back and watching as it potentially pays a dividend out over and over?

If you’re excited by the thought of regular passive income payments, as well as the potential for significant growth on your initial investment…

Then we think you’ll want to see this report inside Motley Fool Share Advisor — ‘5 Essential Stocks For Passive Income Seekers’.

What’s more, today we’re giving away one of these stock picks, absolutely free!

Get your free passive income stock pick

More on Growth Shares

Investing Articles

The Rolls-Royce share price has fallen! Is this the moment investors have been waiting for?

Even the Rolls-Royce share price can't escape current stock market volatility, falling slightly over the last week. Should investors consider…

Read more »

Investing Articles

At a 52-week low but forecast to rise 73%! Is this growth share the FTSE’s top recovery play? 

This FTSE 100 growth share has taken an absolute beating over the past two years but Harvey Jones says the…

Read more »

Investing Articles

Up 19% in 2 weeks, can the Tesla share price rebound further?

Tesla's first-quarter delivery numbers came out today. Will they help persuade our writer to invest his money at the current…

Read more »

Young Black woman looking concerned while in front of her laptop
Investing Articles

£10,000 invested in Raspberry Pi shares at the beginning of 2025 is now worth…

Raspberry Pi shares offer something a little different for UK-focused investors. But while the minicomputer company surged after IPO, it’s…

Read more »

Investing Articles

Up another 53% in a month! Can the Greatland Gold (GGP) share price keep rocketing?

The Greatland Gold (GGP) share price has enjoyed yet another dazzling month and Harvey Jones is captivated, while also warning…

Read more »

Investing Articles

Are things about to go from bad to worse for this legendary FTSE 250 stock?

Aston Martin is an iconic FTSE 250 stock that’s been struggling lately. And it looks as though President Trump’s not…

Read more »

Investing Articles

2 UK shares I’m buying in April

The FTSE 100 and the FTSE 250 have started the year brightly. But could the best opportunities right now still…

Read more »

Person holding magnifying glass over important document, reading the small print
Investing Articles

Is it worth me buying more shares in this FTSE heavyweight after its big Capital Markets Day target updates?

This FTSE firm announced updates to its key strategic targets at its recent Capital Markets day, so is it worth…

Read more »